Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.

Jain P, Fierst TM, Han HJ, Smith TE, Vakil A, Storm PB, Resnick AC, Waanders AJ.

Oncogene. 2017 Nov 9;36(45):6348-6358. doi: 10.1038/onc.2017.276. Epub 2017 Aug 14.

2.

Spontaneous Malignant Transformation of a Pilocytic Astrocytoma of Cerebellum: Case Report.

Coelho J, Nunes S, Salgado D.

Child Neurol Open. 2015 Jan 30;2(1):2329048X14566813. doi: 10.1177/2329048X14566813. eCollection 2015 Jan-Mar.

3.

A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.

Tomić TT, Olausson J, Wilzén A, Sabel M, Truvé K, Sjögren H, Dósa S, Tisell M, Lannering B, Enlund F, Martinsson T, Åman P, Abel F.

PLoS One. 2017 Apr 27;12(4):e0175638. doi: 10.1371/journal.pone.0175638. eCollection 2017. Erratum in: PLoS One. 2017 Sep 7;12 (9):e0184715.

4.

Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine.

Dupain C, Harttrampf AC, Urbinati G, Geoerger B, Massaad-Massade L.

Mol Ther Nucleic Acids. 2017 Mar 17;6:315-326. doi: 10.1016/j.omtn.2017.01.005. Epub 2017 Feb 9. Review.

5.

A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.

Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH, Ramkissoon LA, Garcia VM, Mazzola E, Goumnerova L, Kane M, Yao Z, Kieran MW, Ligon KL, Hahn WC, Garraway LA, Rosen N, Gray NS, Agar NY, Buhrlage SJ, Segal RA, Stiles CD.

Neuro Oncol. 2017 Jun 1;19(6):774-785. doi: 10.1093/neuonc/now261.

PMID:
28082416
6.

Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway.

Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N, Lavi E, Saffery R, Sexton-Oates A, Blumcke I, Capper D, Karajannis MA, Benayed R, Chavez L, Thomas C, Serrano J, Borsu L, Ladanyi M, Rosenblum MK.

Acta Neuropathol. 2017 Mar;133(3):417-429. doi: 10.1007/s00401-016-1639-9. Epub 2016 Nov 3.

7.

MicroRNA profiling of low-grade glial and glioneuronal tumors shows an independent role for cluster 14q32.31 member miR-487b.

Ames HM, Yuan M, Vizcaíno MA, Yu W, Rodriguez FJ.

Mod Pathol. 2017 Feb;30(2):204-216. doi: 10.1038/modpathol.2016.177. Epub 2016 Oct 14.

8.

Perinatal (fetal and neonatal) astrocytoma: a review.

Isaacs H Jr.

Childs Nerv Syst. 2016 Nov;32(11):2085-2096. Epub 2016 Aug 27. Review.

9.

BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.

Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Stalpers LJ, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA.

Clin Cancer Res. 2016 Nov 1;22(21):5312-5321. Epub 2016 May 23.

10.

Whole Chromosome 7 Gain Predicts Higher Risk of Recurrence in Pediatric Pilocytic Astrocytomas Independently From KIAA1549-BRAF Fusion Status.

Roth JJ, Fierst TM, Waanders AJ, Yimei L, Biegel JA, Santi M.

J Neuropathol Exp Neurol. 2016 Apr;75(4):306-15. doi: 10.1093/jnen/nlw001. Epub 2016 Mar 4.

11.

Landscape of gene fusions in epithelial cancers: seq and ye shall find.

Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM.

Genome Med. 2015 Dec 18;7:129. doi: 10.1186/s13073-015-0252-1. Review.

12.

Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.

Gajjar A, Bowers DC, Karajannis MA, Leary S, Witt H, Gottardo NG.

J Clin Oncol. 2015 Sep 20;33(27):2986-98. doi: 10.1200/JCO.2014.59.9217. Epub 2015 Aug 24. Review.

13.

Clinicopathologic implications of NF1 gene alterations in diffuse gliomas.

Vizcaíno MA, Shah S, Eberhart CG, Rodriguez FJ.

Hum Pathol. 2015 Sep;46(9):1323-30. doi: 10.1016/j.humpath.2015.05.014. Epub 2015 May 30.

14.

BRAF gene: From human cancers to developmental syndromes.

Hussain MR, Baig M, Mohamoud HS, Ulhaq Z, Hoessli DC, Khogeer GS, Al-Sayed RR, Al-Aama JY.

Saudi J Biol Sci. 2015 Jul;22(4):359-73. doi: 10.1016/j.sjbs.2014.10.002. Epub 2014 Oct 23. Review.

15.

KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.

Becker AP, Scapulatempo-Neto C, Carloni AC, Paulino A, Sheren J, Aisner DL, Musselwhite E, Clara C, Machado HR, Oliveira RS, Neder L, Varella-Garcia M, Reis RM.

J Neuropathol Exp Neurol. 2015 Jul;74(7):743-54. doi: 10.1097/NEN.0000000000000213.

16.

A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†.

Chintagumpala M, Eckel SP, Krailo M, Morris M, Adesina A, Packer R, Lau C, Gajjar A.

Neuro Oncol. 2015 Aug;17(8):1132-8. doi: 10.1093/neuonc/nov057. Epub 2015 Apr 7.

17.

The BRAF kinase domain promotes the development of gliomas in vivo.

Shin CH, Grossmann AH, Holmen SL, Robinson JP.

Genes Cancer. 2015 Jan;6(1-2):9-18.

18.

Pilocytic astrocytoma: pathology, molecular mechanisms and markers.

Collins VP, Jones DT, Giannini C.

Acta Neuropathol. 2015 Jun;129(6):775-88. doi: 10.1007/s00401-015-1410-7. Epub 2015 Mar 20. Review.

19.

Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas.

Penman CL, Faulkner C, Lowis SP, Kurian KM.

Front Oncol. 2015 Mar 3;5:54. doi: 10.3389/fonc.2015.00054. eCollection 2015. Review.

20.

BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.

Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, Stavropoulos J, Alon N, Pole JD, Ray PN, Navickiene V, Mangerel J, Remke M, Buczkowicz P, Ramaswamy V, Guerreiro Stucklin A, Li M, Young EJ, Zhang C, Castelo-Branco P, Bakry D, Laughlin S, Shlien A, Chan J, Ligon KL, Rutka JT, Dirks PB, Taylor MD, Greenberg M, Malkin D, Huang A, Bouffet E, Hawkins CE, Tabori U.

J Clin Oncol. 2015 Mar 20;33(9):1015-22. doi: 10.1200/JCO.2014.58.3922. Epub 2015 Feb 9.

Supplemental Content

Support Center